Controversy Over Adjuvant CDK4/6 Inhibitors in HER2-Negative Breast Cancer

36 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this video, John M. Burke, MD, Rocky Mountain Cancer Centers Associate Chair US Oncology Hematology Research Program in Aurora, Colorado, discusses the controversy surrounding the use of adjuvant CDK4/6 inhibitors ribociclib [Kisqali] and abemaciclib [Verzenio] for the treatment of HER2-negative breast cancer. Burke highlights 2 published articles that address design flaws in the phase 3 monarchE [NCT03155997] and phase 3 NATALEE [NCT03701334] trials, as well as the high costs associated with these treatments despite the uncertainty of achieving effective results.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Categoria
Oncology
Commenta per primo questo video.

Prossimo